Search

Your search keyword '"Kenneth Lebioda"' showing total 100 results
Start Over "Kenneth Lebioda"
100 results on '"Kenneth Lebioda"'

53. Resverlogix Announces Voting Results

Subjects
Company earnings/profit, Business, News, opinion and commentary
Abstract

TSX Exchange Symbol: RVX CALGARY, Oct. 3, 2013 /PRNewswire/ - Resverlogix Corp. (the 'Corporation') (TSX:RVX) today announced that, at its annual and special meeting of shareholders held on October 3, [...]

Published
2013

55. Resverlogix Announces a Corporate Update Conference Call & Webcast

Subjects
Cholesterol, Business, News, opinion and commentary
Abstract

TSX Exchange Symbol: RVX CALGARY, Aug. 29, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced they will be hosting a corporate update conference call and webcast with Q&A on September [...]

Published
2013

56. Zenith Epigenetics Corp. commences operations

Subjects
Business, News, opinion and commentary
Abstract

CALGARY, June 3, 2013 /PRNewswire/ - Zenith Epigenetics Corp. ('Zenith') commenced operations today as an early stage research company. Zenith was formed as a result of a plan of arrangement [...]

Published
2013

57. Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

Subjects
Business, Business, international, News, opinion and commentary
Abstract

(From Canada Newswire) Byline: Andy Reid CALGARY and ATLANTA , May 19 /CNW/ - Resverlogix Corp. ('Resverlogix' or the 'Company') (TSX:RVX) is pleased to announce today that it has made [...]

Published
2009

58. Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

Subjects
Business, News, opinion and commentary
Abstract

Novel small molecules illustrate potential cost effective approach for rheumatoid arthritis TSX Exchange Symbol: RVX CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ -- Resverlogix Corp. ('Resverlogix' or the 'Company') (TSX:RVX) is [...]

Published
2009

60. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

Subjects
Business, Business, international, News, opinion and commentary
Abstract

(From Canada Newswire) Byline: Richard Metcalf CALGARY , Nov. 10 /CNW/ - Resverlogix Corp. ('Resverlogix') (TSX:RVX) announced today that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL [...]

Published
2008

62. Industry Leaders Select Resverlogix's RVX-208

Subjects
Business, News, opinion and commentary
Abstract

Among top 10 most promising drugs TSX Exchange Symbol: RVX CALGARY, July 9 /PRNewswire-FirstCall/ -- Resverlogix Corp's ('Resverlogix' or the 'Company') (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been [...]

Published
2008

63. Stella M. Thompson Joins Resverlogix Board of Directors

Subjects
Boards of directors -- Appointments, resignations and dismissals
Abstract

CALGARY, ALBERTA, Sep 17, 2007 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX) is pleased to announce today that Stella Thompson has joined the Board of Directors. On […]

Published
2007

65. Resverlogix Corp.: First Ever Therapy Targets Optic Nerve Head for Glaucoma

Subjects
Glaucoma -- Care and treatment, Ophthalmology, Bone morphogenetic proteins
Abstract

CALGARY, ALBERTA, Sep 10, 2007 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX) is pleased to announce positive results from preliminary proof-of-concept studies for Resverlogix's TGF-Beta Shield (TM) […]

Published
2007

70. Resverlogix Collaborates NexVas(TM) AD Program with Leading Alzheimer's Researcher at Sun Health Research Institute; Dr. Larry Sparks first to identify the link between cholesterol and Alzheimer's disease

Subjects
Cholesterol, Medical research, Medicine, Experimental, Clinical trials, Alzheimer's disease, Research institutes
Abstract

CALGARY, ALBERTA, Jun 19, 2007 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX) is pleased to announce today that it has signed a collaborative research agreement with Dr. […]

Published
2007

71. Dr. Roger Newton, Co-Discoverer of Lipitor(R), Joins Resverlogix Board of Directors

Subjects
Blood lipoproteins, Proteolipids, Cardiovascular diseases, Boards of directors, Lipoproteins, Atherosclerosis
Abstract

CALGARY, ALBERTA, May 14, 2007 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX) is pleased to announce today that the Board of Directors has appointed Roger Newton, PhD, […]

Published
2007

73. Resverlogix Announces Milestone ApoA-l/HDL Proof-of-Concept Data

Subjects
Business, Business, international
Abstract

(From Hugin) NexVas(TM) PR lead molecule RVX-208 increases ApoA-l/HDL in monkeys CALGARY, ALBERTA -- (MARKET WIRE) -- April 25, 2007 -- Resverlogix Corp. ('Resverlogix') (TSX: RVX) announced today that the [...]

Published
2007

75. Resverlogix Corp.: American College of Cardiology Meeting Highlights the Need for ApoA-I Enhancement Small Molecules; CETP failure demonstrate ApoA-l focused therapeutics clearly differentiated as the key target for cardiovascular disease risk reduction

Subjects
Homeopathy -- Materia medica and therapeutics, Therapeutics, Cardiovascular diseases -- Risk factors
Abstract

CALGARY, ALBERTA, Apr 02, 2007 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX) released today that subsequent to important findings announced last week from numerous presentations at the […]

Published
2007

81. Resverlogix Corp.: RVX208 Unique MOA Positions it as a Leader in ApoA-I/HDL Marketplace; Hundreds of thousands of patients in key landmark trials demonstrate that enhanced ApoA-I significantly reduces cardiovascular disease risk

Subjects
Cholesterol, Cardiovascular diseases -- Risk factors, Cardiac patients
Abstract

CALGARY, ALBERTA, Dec 05, 2006 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action (MOA) is well […]

Published
2006

84. Resverlogix Corp. First Lead RVX-208 Raises ApoA-I up to 180%

Subjects
Atherosclerosis
Abstract

CALGARY, ALBERTA, Sep 28, 2006 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX), is pleased to announce today that its first lead candidate RVX-208 has illustrated the ability […]

Published
2006

85. Resverlogix Corp. Granted Foreign Private Issuer Status

Abstract

CALGARY, ALBERTA, Aug 23, 2006 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX), has applied for and been granted Foreign Private Issuer status by the US Securities Exchange […]

Published
2006

86. ResVerlogix Corp. Announces Live Webcast Update

Abstract

CALGARY, ALBERTA, Jul 24, 2006 (MARKET WIRE via COMTEX) -- ResVerlogix Corp. ('Resverlogix') (TSX: RVX), an emerging international leader in cardiovascular research, announced today that it will host a live […]

Published
2006

87. Resverlogix Corp. Announces License Agreement with Medtronic

Subjects
Company licensing agreement, Medtronic PLC -- Licensing agreements, Medical equipment -- Licensing agreements, Medical test kit industry -- Licensing agreements, Medical equipment and supplies industry -- Licensing agreements, Cardiovascular diseases, Physiological apparatus -- Licensing agreements
Abstract

CALGARY, ALBERTA, Jul 19, 2006 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ('Resverlogix') (TSX: RVX), on behalf of its subsidiary RVX Therapeutics Inc ('RVX'), is pleased to announce today the […]

Published
2006

90. Resverlogix Corp. Expands NexVas'TM' ApoA-I Program into Stroke

Subjects
Stroke (Disease)
Abstract

CALGARY, ALBERTA, May 03, 2006 (MARKET WIRE via COMTEX) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), is pleased to announce today it will expand its research and development program for its lead […]

Published
2006

93. Resverlogix Corp. Launches NEXVAS'TM' Education Program

Subjects
Business, Business, international
Abstract

CALGARY, Alberta -- Resverlogix Corp. (TSX:RVX), is pleased to announce that it has developed and launched a technical animation on its lead technology NEXVAS(TM). The animation will provide interested parties [...]

Published
2005

94. Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent

Subjects
Intellectual property, Product development, Patent/copyright issue, Clinical trials, Statins, Patents
Abstract

rstCall/ - Resverlogix Corp. ('Resverlogix' or the 'Company') (TSX:RVX) is pleased to announce that it has filed additional new patent protection based on novel findings derived from its recently completed [...]

Published
2010

95. Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

Subjects
Intellectual property, Patent/copyright issue, Inflammation, Patents, Arthritis
Abstract

Resverlogix Corp. ('Resverlogix' or the 'Company') (TSX:RVX) is pleased to announce that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases. Two new [...]

Published
2009

96. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

Subjects
Analysis, Medical research -- Analysis, Alzheimer's disease -- Analysis, Medicine, Experimental -- Analysis
Abstract

Resverlogix Corp. ('Resverlogix') (TSX:RVX) announced that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a clinical trial found [...]

Published
2008

97. Small molecule therapeutics for CVD and inflammatory diseases

Subjects
Homeopathy -- Materia medica and therapeutics, Biotechnology industry -- Product introduction -- Technology application, Therapeutics -- Product introduction, Cardiovascular diseases -- Care and treatment, Low density lipoproteins -- Care and treatment -- Technology application, Technology application, Business, High technology industry
Abstract

Cardiovascular disease (CVD) is a leading cause of death in the developed world. Currently used CVD therapies target low-density lipoprotein (LDL), an important marker for CVD risk reduction. But such [...]

Published
2007

98. Resverlogix Announces Alzheimer's Research Program

Subjects
Research, Medical research, Alzheimer's disease -- Research, Medicine, Experimental
Abstract

Resverlogix Corp. ('Resverlogix') (TSX:RVX) is pleased to announce that it has initiated a research program dedicated to ApoA-I production and its therapeutic potential for disorders that effect cognitive function such [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results